Looking very very promising -
Importantly, in these patients, changes in tumour burden
correlated with systemic immunological changes known to promote anti-tumour
immunity. The poster "Oncolytic Virus CF33-hNIS Monotherapy for the Treatment of
Gastrointestinal Malignancies" will be presented on 18 January 2024 during Session
A: Cancers of the Esophagus and Stomach and Other GI Cancers from 11:45 AM-1:15
PM.
Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-18
-
- There are more pages in this discussion • 160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.1¢ | $717.6K | 13.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1468251 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 457393 | 5 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |